Concentration‐QTcF analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia
Abstract Quizartinib prolongs QT interval through inhibition of the slow delayed rectifier potassium current (IKs). We used non‐linear mixed‐effects modeling to explore the relationship between quizartinib and its pharmacologically active metabolite AC886 and the Fridericia‐corrected QT interval (QT...
Saved in:
Main Authors: | Pavan Vaddady, Giovanni Smania, Shintaro Nakayama, Hiroyuki Inoue, Abhinav Kurumaddali, Malaz Abutarif, Ming Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-11-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.70065 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia
by: Pavan Vaddady, et al.
Published: (2024-12-01) -
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
by: Jorge Cortes
Published: (2024-11-01) -
FLT3 INTERNAL TANDEM DUPLICATION AND D835 MUTATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND ITS CLINICAL SIGNIFICANCE
by: Ghaleb Elyamany, et al.
Published: (2014-05-01) -
Characterization of the FLT3 Mutation in Newly Diagnosed Patients with Acute Myeloid Leukemia
by: Luay Fahad, et al.
Published: (2024-06-01) -
Evolution of CpG-islands by means of tandem duplications
by: V. N. Babenko, et al.
Published: (2017-02-01)